Document is current
Any future updates will be listed below
-
Authors
Nixon, Andrew B.
Navarro, Fábio C. P.
Zhou, Katherine I.
Abbott, Charles W.
McDaniel, Lee
Ravi, Neeraja
Howard, Lauren E.
Brady, J. Christopher
Liu, Yingmiao
Jia, Jingquan
Niedzwiecki, Donna
Strickler, John H.
Boyle, Sean M.
Chen, Richard O.
Uronis, Hope
-
Funding
Funding for this research was provided by:
Duke Hematology & Transfusion Medicine Training Program (NHLBI T32 HL007057)
- License Information
-
More Information
Article History
Received: 14 January 2026
Accepted: 2 March 2026
First Online: 23 March 2026
Declarations
:
: ABN has received research funding from Genentech, Genmab, MedImmune/AstraZeneca, Seattle Genetics, and has received consultant/advisory compensation from Sanofi and Leap Therapeutics. LM has stock in Personalis and other intellectual property. JJ has received research funding from Bayer, Incyte, Roche/Genentech, and Xilis. JHS has received research funding or contracted research from Abbvie, Amgen, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Revolution Medicines, Roche/Genentech, Seagen; has received consultant/advisory compensation from Abbvie, Agenus, Astellas, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GSK, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics; and has received stocks from Triumvira Immunologics. HU has received research funding from Adaptimmune, Arcus Biosciences, Bristol-Myers Squibb, Genentech/Roche, Leap Therapeutics, Macrogenics, Merck; and has received consultant/advisory compensation from AstraZeneca and Bristol-Myers Squibb/Medarex. FCPN, CA, LM, NR, SMB, ROC are employed by and have received stocks from Personalis, Inc. The other authors declared no conflicts of interest.
